Manufacturing Equipment, Biologics

The completed expansion at AGC Biologics'Copenhagen, Denmark, site, doubles the company's single-use bioreactor capacity for mammalian-based services.

Lars Petersen, CEO, FUJIFILM Diosynth Biotechnologies discusses the company’s strategic goals and meeting market demand for mammalian cell culture capacity.

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.

Global product manager at Cytiva, Eric Corti, discusses the challenges with designing a new single-use mixing system that ensures leak-free fluid handling operations at INTERPHEX 2024.

The improvement of ADC manufacturing now demands increased containment requirements and continually advancing analytical detection of molecules in manufacturing spaces.

The Xcellerex magnetic mixer, single-use mixing system was designed to address challenges in large-scale mAb, vaccine, and genomic medicine manufacturing processes.

WMFTS has launched WMArchitect, a single-use product line that offers ready-to-use single-use assemblies and custom-designed workflows for biopharma fluid management.

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Challenges in fermentation can be addressed through equipment changes, facility design, and process development.

Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.

Pharmaceutical Technology Europe® spoke with Fiona Bellot, sales director, Cellexus BioreactorSystems, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Digital transformation allows for smarter and connected biomanufacturing operations.

As part of a $30 million investment, Aragen is setting up a new biologics manufacturing facility in Bangalore, India.

SCHOTT now offers ViewCell, a new component meant to add flexibility to biopharmaceutical process control.

The bioreactors can integrate with Emerson’s DeltaV PK Controller in addition to S-Series and M-Series controllers.

The new excipients manufacturing facility is expected to be completed in 2025.

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics

Alternative approaches to freeze-drying are gaining popularity and will help to overcome some of the challenges associated with conventional lyophilization.

The trends shaping the growth of the biologics outsourcing industry demand attention.

Scorpion’s new facility is designed for the development and manufacturing of clinical and commercial-scale biologic drugs.

Choosing low-adsorption glass vials helps ensure detection accuracy.

Getinge’s new DPTE-EXO with Sleeveless DPTE-BetaBag is an alpha port with an external opening and an integrated funnel for automated aseptic transfer.

Flexible and efficient methods are needed for biopharmaceutical manufacturing.

The struggle to implement continuous biomanufacturing at GMP level is slowly advancing.

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

PharmTech interviewed Sartorius about SUS innovations and trends.

Training is crucial for supporting GMP operations in commercial-scale bioprocessing.